PT2190475E - Métodos de melhoramento da capacidade adjuvante de composições de vacinas - Google Patents

Métodos de melhoramento da capacidade adjuvante de composições de vacinas Download PDF

Info

Publication number
PT2190475E
PT2190475E PT88757372T PT08875737T PT2190475E PT 2190475 E PT2190475 E PT 2190475E PT 88757372 T PT88757372 T PT 88757372T PT 08875737 T PT08875737 T PT 08875737T PT 2190475 E PT2190475 E PT 2190475E
Authority
PT
Portugal
Prior art keywords
adjuvanticity
enhancing
methods
vaccine compositions
vaccine
Prior art date
Application number
PT88757372T
Other languages
English (en)
Inventor
Vincent Serra
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of PT2190475E publication Critical patent/PT2190475E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT88757372T 2007-08-29 2008-08-29 Métodos de melhoramento da capacidade adjuvante de composições de vacinas PT2190475E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29

Publications (1)

Publication Number Publication Date
PT2190475E true PT2190475E (pt) 2016-02-11

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88757372T PT2190475E (pt) 2007-08-29 2008-08-29 Métodos de melhoramento da capacidade adjuvante de composições de vacinas

Country Status (14)

Country Link
US (1) US8916164B2 (pt)
EP (1) EP2190475B1 (pt)
JP (1) JP5539890B2 (pt)
KR (1) KR101540081B1 (pt)
CN (1) CN101820909A (pt)
AU (1) AU2008360937B9 (pt)
BR (1) BRPI0815846A2 (pt)
ES (1) ES2558157T3 (pt)
HR (1) HRP20151356T1 (pt)
PL (1) PL2190475T3 (pt)
PT (1) PT2190475E (pt)
RU (1) RU2491090C2 (pt)
WO (1) WO2010023498A1 (pt)
ZA (1) ZA201001477B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820960B8 (pt) 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
EP2842961B1 (en) 2012-04-26 2016-12-14 Riken New carbamate glycolipid and use thereof
AU2022228420A1 (en) 2021-03-01 2023-10-05 Deciduous Therapeutics, Inc. Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) * 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (en) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
EP0694558B1 (en) * 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
EP0698031A4 (en) * 1993-05-14 1997-07-09 Cytel Corp SIALYL LEx ANALOGS AS INHIBITORS OF CELLULAR ADHESION
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) * 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) * 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
CA2280130C (en) 1997-02-05 2007-12-18 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
KR100527950B1 (ko) * 1997-04-10 2005-11-09 기린 비루 가부시키가이샤 알파-글리코실세라미드를 함유하는 엔케이티 세포활성화제
CA2316041A1 (en) 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
DE69943314D1 (de) * 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
CA2389652A1 (en) * 1999-10-12 2001-04-19 National Research Council Of Canada Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte(ctl) responses and protect the vaccinated host against intracellular pathogens and cancer
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1277472A4 (en) * 2000-04-28 2005-06-08 Orient Cancer Therapy Co Ltd REMEDIES AGAINST CANCER
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
US20020115624A1 (en) * 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
AR034413A1 (es) * 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
CA2469406A1 (en) * 2001-11-06 2003-05-15 Orient Cancer Therapy Co., Ltd. Anticancer compositions
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
AU2005235080A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
DE602005020643D1 (de) * 2004-09-03 2010-05-27 Univ Chicago Verfahren zur aktivierung von nkt-zellen
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
DK1848813T3 (da) 2005-01-28 2013-07-15 Univ Brigham Young Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
CA2626997C (en) 2005-10-25 2014-12-23 Ludwig Institute For Cancer Research Analogs of alpha galactosylceramide and uses thereof
US8227581B2 (en) 2006-04-07 2012-07-24 The Scripps Research Institute Modified α-galactosyl ceramides for staining and stimulating natural killer T cells
CN101426523B (zh) 2006-04-27 2013-03-27 财团法人首尔大学校产学协力财团 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗
WO2008005824A1 (en) 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
BRPI0820960B8 (pt) * 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza

Also Published As

Publication number Publication date
HRP20151356T1 (hr) 2016-01-01
KR20100072211A (ko) 2010-06-30
ZA201001477B (en) 2010-12-29
RU2010111766A (ru) 2011-10-10
AU2008360937B9 (en) 2014-02-13
US20100285042A1 (en) 2010-11-11
WO2010023498A8 (en) 2010-04-15
JP5539890B2 (ja) 2014-07-02
BRPI0815846A2 (pt) 2017-05-30
AU2008360937A1 (en) 2010-03-04
WO2010023498A1 (en) 2010-03-04
JP2011518760A (ja) 2011-06-30
KR101540081B1 (ko) 2015-07-29
PL2190475T3 (pl) 2016-04-29
EP2190475B1 (en) 2015-10-28
CN101820909A (zh) 2010-09-01
RU2491090C2 (ru) 2013-08-27
AU2008360937A2 (en) 2010-04-29
ES2558157T3 (es) 2016-02-02
AU2008360937B2 (en) 2014-01-16
EP2190475A1 (en) 2010-06-02
US8916164B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
HK1249031A1 (zh) 疫苗施用的方法
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200808489B (en) Nicotine-carrier vaccine formulation
EP2376089A4 (en) CANCER VACCINE COMPOSITIONS AND THEIR METHODS OF USE
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
GB0700135D0 (en) Vaccine
GB0810869D0 (en) Vaccine adjuvant composition
EP2334332A4 (en) NEW COMPOSITIONS AND NEW ADJUVANTS
IL214127A0 (en) Vaccine compositions
EP2252326A4 (en) VACCINE COMPOSITIONS
GB0805356D0 (en) Vaccine adjuvant composition
EP2498815A4 (en) VACCINE COMPOSITION
EP2097103A4 (en) VACCINE FORMULATIONS AGAINST INFLUENZA
GB0710538D0 (en) Vaccine
ZA201001477B (en) Methods of enhancing adjuvanticity of vaccine compositions
IL220308A0 (en) Vaccine compositions
EP2337847A4 (en) ADJUVANTS FOR VACCINES
GB0819079D0 (en) Gypsum based formulations
GB0606856D0 (en) Vaccine compositions
GB0801122D0 (en) Vaccine composition
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0820404D0 (en) Vaccine compositions
GB0601035D0 (en) Method of vaccine preparation
GB0702363D0 (en) Vaccine composition
GB0802326D0 (en) Vaccine Composition